VRTX

NASDAQ · Biotechnology

Vertex Pharmaceuticals Inc

S&P 500 Nasdaq 100 Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks

$436.95

-13.46 (-2.99%)

As of May 16, 1:01 AM ET ·

Financial Highlights (FY 2026)

Revenue

12.17B

Net Income

4.01B

Gross Margin

86.2%

Profit Margin

32.9%

Rev Growth

+10.4%

D/E Ratio

0.01

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	86.2%	86.2%	56.9%	56.9%
Operating Margin	34.8%	31.3%	11.0%	10.1%
Profit Margin	32.9%	31.3%	8.5%	11.0%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	12.17B	11.03B	15.93B	17.43B
Gross Profit	10.50B	9.51B	9.06B	9.91B
Operating Income	4.23B	3.45B	1.76B	1.76B
Net Income	4.01B	3.27B	1.35B	1.92B
Gross Margin	86.2%	86.2%	56.9%	56.9%
Operating Margin	34.8%	31.3%	11.0%	10.1%
Profit Margin	32.9%	31.3%	8.5%	11.0%
Rev Growth	+10.4%	+10.4%	-6.3%	+21.6%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	340.90M	340.90M	13.83B	14.35B
Total Equity	56.82B	56.82B	91.42B	88.18B
D/E Ratio	0.01	0.01	0.15	0.16

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	4.45B	3.83B	2.28B	2.59B
Free Cash Flow	—	—	1.35B	2.40B